In a phase II trial, three groups of patients were formed according to their microsatellite status—MSI-H, non-MSI-H, and MSS CRC—in order to test the clinical activity of anti-PD1 MoAb, Pembrolizumab. The gene discussed is PDCD1; the disease is colorectal carcinoma.